Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
1998-06-19
2003-10-28
Shukla, Ram R. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C435S001100, C424S093700, C424S093210
Reexamination Certificate
active
06638501
ABSTRACT:
BACKGROUND OF THE INVENTION
Cell transplantation is increasingly becoming a therapy of choice for a variety of cell-based disorders ranging from sickle cell anemia and diabetes to Parkinson's disease. For example, cell lines may be transplanted to deliver a biologically active agent such as insulin, for the treatment of diabetes; parathyroid hormone, for treatment of hypoparathyroidism; erythropoietin, for treatment of anemia; and gamma-amino-butyric acid, for treatment of epilepsy. The cells may naturally secrete the biologically active molecule, or be genetically modified to do so. There are several obstacles that prevent cell transplantation therapy from realizing its full potential. For example, obtaining quantities of cells suitable for transplantation is often a problem. Cell lines transformed with oncogenes can pose a risk of unwanted cell migration, unrestricted proliferation, and possibly tumor formation. Transplant rejection is also a potential problem. These problems have been addressed by encapsulating the transplanted cells in immunoisolatory vehicles which retain the cells at a desired location within the transplant recipient, where the cells secrete the biologically active substances. The immunoisolatory vehicle prevents unwanted cell migration, possible tumor formation, and reduces the possibility of transplant rejection. Methods of transplanting encapsulated cells are disclosed in U.S. Pat. No. 5,550,050.
For some cell-based disorders, it is necessary for the transplanted cells to become integrated with the host tissue being treated. In these cases, encapsulation methods cannot be used. Thus, it is important that the transplanted cells are human leukocyte antigen (HLA) matched to the patient's tissue to reduce the likelihood of transplant rejection. Hematopoietic stem cell transplantation, is an example of a therapy where donor cells become integrated with the patient's own tissue. It is an effective therapy for a number of diseases, such as sickle cell anemia, aplastic anemia, and a variety of immunodeficiency disorders, including those which result from treatments for other disorders such as chemo- and radiotherapy treatment for cancer (reviewed in Amos and Gordon,
Cell Transplantation
4(6):547-569 (1995)). Hematopoietic stem cells, are present in adult bone marrow and blood (in smaller numbers), and are capable of giving rise to all of the cells of the hematopoietic cell lineage. Fetal sources of hematopoietic stem cells in umbilical cord blood and liver, have also been reported. Lu et al.,
Critical Rev. in Oncol./Hemataol
. 22:61-78 (1996).
Certain neurological disorders treated by cell transplantation, also require that the cells become integrated with the host tissue. For example, in the treatment of myelin deficiencies, it is necessary for the transplanted cells to reform the insulating cellular sheaths around the axons of demyelinated neurons. Animal models of myelin deficiencies have shown promising results from the transplantation of undifferentiated neural stem cell progeny into demyelinated regions of the central nervous system. Hammang et al.,
Experimental Neurology
147:84-95 (1997).
Several tissues in the body contain stem cells. The primary role of stem cells in adults is to replace cells which have been lost by natural cell death, injury or disease. Stem cells have been defined as “undifferentiated cells capable of a) proliferation, b) self-maintenance, c) the production of a large number of differentiated, functional progeny, d) regenerating tissue after injury, and e) a flexibility in the use of these options”. Potten and Loeffler,
Development
, Vol. 110, ¶. 1001-1020 (1990). Stem cells isolated from the early embryonic blastula, i.e. prior to gastrulation, can produce cell types of all different lineages (for review see Keller, G. M.
Curr. Opin. Cell Biol
. 7:862-869 (1995)). More recently, it has been hypothesized that neural tissue is likely to be the default state for all cells during early embryonic development. Green,
Cell
77:317-320 (1994); Hemmati-Brivanlou & Melton,
Cell
88:13-17 (1997). However, in the adult, it is generally believed stem cells present in a specific tissue are restricted to produce cell types of that tissue. For example, hematopoietic stem cells derived from adult bone marrow give rise to progeny of the blood, immune system, and myogenic precursors, but have not been reported to give rise to other tissue types. Ferrari et al.
Science
279:1528-1530 (1998). Similarly, adult neural stem cells obtained from neural tissue have only been reported to give rise to neural specific cell types.
In addition to the treatment of various cell-based diseases and disorders, cell transplantation could also be potentially useful for treating injuries and/or strengthening, or otherwise, augmenting various tissues such as, skin, heart muscle, and bone. However, lack of availability of sufficient quantities of compatible, healthy cells of the required phenotype, which can become integrated with the desired tissue, prevents cell transplantation therapies from reaching their full potential. For example, in the treatment of bone marrow diseases, it is difficult to find well-matched donors who are willing to be subjected to the painful and time-consuming bone marrow donation process.
A reliable source of cells that can be used for transplantation, with reduced risk of rejection, to replace or augment cells in a variety of tissues is needed.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a source of stem cells that can be used to augment any type of mammalian tissue including, but not limited to, bone marrow, liver, thymus, spleen, pancreas, heart muscle, lung, skin, skeletal muscle, smooth muscle, gonadal, intestinal, central nervous system (CNS), and lymph tissue. It is also an object of the invention that the stem cells be obtainable from autologous, allogeneic, or xenogeneic tissue, and readily proliferated ex vivo to generate a sufficient number of cells for tissue augmentation.
These objects are achieved by providing methods for augmenting one or more tissues of a mammal by administering multipotent neural stem cell (MNSC) progeny to the mammal and allowing the MNSC progeny to integrate with the tissue. The MNSC progeny can be administered to the mammal by any suitable method. For example, the cells can be administered systemically, where they migrate to tissues requiring augmentation, they can be applied close to the periphery of the tissue to be augmented, or injected or applied directly to the tissue to be augmented. In the treatment or augmentation of CNS tissue, MNSC progeny can be administered outside the CNS, and migrate to the CNS and differentiate into CNS cells.
Methods for generating differentiated non-neural mammalian cells from MNSC progeny are also provided which comprise placing the multipotent neural stem cell progeny in an environment that induces them to produce the differentiated non-neural cells.
REFERENCES:
patent: 5550050 (1996-08-01), Holland et al.
patent: 5650135 (1997-07-01), Contag et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 6093531 (2000-07-01), Bjornson et al.
patent: WO93/01275 (1993-01-01), None
Holyoake TL et al. Exp Hematology 27:1418-1427, 1999.*
Clarke DL et al. Science 288:1660-1663, 2000).*
Gage FH. Science 287:1433-1438, 2000.*
Bjornson CRR et al. Science 283:534-537, 1999.*
Amos, T.A.S., et al., “Source of Human Hematopoietic Stem Cells for Transplantation—A Review”,Cell Trans.,4(6):547-569 (1995).
Bensinger, William, et al., “Factors That Influence Collection and Engraftment of Autologous Peripheral-Blood Stem Cells”,J. Clin. Oncol.,13(10):2547-2555 (Oct. 1995).
Chalfie, Martin, et al., “Green Fluorescent Protein as a Marker for Gene Expression”,Sci.,263:802-805 (Feb. 1994).
Ferrari, Giuliana, et al., “Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors”,Sci.,279:1528-1530 (Mar. 1998).
Green, Jeremy B.A., et al., “Roads to Neuralness: Embryonic Neural Induction as Derepression of a Default State”,Cell,77:317-320 (May 19
Bjornson Christopher R.
Reynolds Brent A.
Rietze Rod L.
Vescovi Angelo L.
Elrifi, Esq. Ivor R.
Karnakis, Esq. Christina V.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Neurospheres Holdings Ltd.
Shukla Ram R.
LandOfFree
Use of multipotent neural stem cell progeny to augment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of multipotent neural stem cell progeny to augment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of multipotent neural stem cell progeny to augment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3155706